179 related articles for article (PubMed ID: 36036471)
41. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
[TBL] [Abstract][Full Text] [Related]
42. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
43. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
Winston DJ; Bartoni K; Territo MC; Schiller GJ
Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
[TBL] [Abstract][Full Text] [Related]
44. Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.
Jeong W; Snell GI; Levvey BJ; Westall GP; Morrissey CO; Wolfe R; Ivulich S; Neoh CF; Slavin MA; Kong DCM
J Antimicrob Chemother; 2018 Mar; 73(3):748-756. PubMed ID: 29211913
[TBL] [Abstract][Full Text] [Related]
45. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness.
Cadena J; Levine DJ; Angel LF; Maxwell PR; Brady R; Sanchez JF; Michalek JE; Levine SM; Restrepo MI
Am J Transplant; 2009 Sep; 9(9):2085-91. PubMed ID: 19645709
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of target attainment of oral posaconazole suspension in immunocompromised children.
Lai T; Alffenaar JW; Kesson A; Bandodkar S; Roberts JA
J Antimicrob Chemother; 2020 Mar; 75(3):726-729. PubMed ID: 31855264
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis.
Zhang H; Nguyen MH; Clancy CJ; Joshi R; Zhao W; Ensor C; Venkataramanan R; Shields RK
Antimicrob Agents Chemother; 2016 Jun; 60(6):3558-62. PubMed ID: 27021324
[TBL] [Abstract][Full Text] [Related]
48. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study.
Lerolle N; Raffoux E; Socie G; Touratier S; Sauvageon H; Porcher R; Bretagne S; Bergeron A; Azoulay E; Molina JM; Lafaurie M
Clin Microbiol Infect; 2014 Nov; 20(11):O952-9. PubMed ID: 24861577
[TBL] [Abstract][Full Text] [Related]
49. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.
Yi WM; Schoeppler KE; Jaeger J; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):60. PubMed ID: 28893246
[TBL] [Abstract][Full Text] [Related]
50. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
Liebenstein TK; Widmer KM; Fallon MJ
J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia.
Le Clech L; Uguen M; Quinio D; Nevez G; Couturier MA; Ianotto JC; Berthou C; Guillerm G; Le Bars H; Payan C; Narbonne V; Baron R; Saliou P
Curr Res Transl Med; 2020 Jan; 68(1):23-28. PubMed ID: 31787568
[TBL] [Abstract][Full Text] [Related]
52. Optimizing antifungal prophylaxis in allogeneic stem cell transplantation: A cohort study of two different approaches.
Selby PR; Warner MS; Peake SL; Bardy P; Hiwase D; Singhal D; Beligaswatte A; Hahn U; Roberts JA; Yeung D; Shakib S
Transpl Infect Dis; 2022 Dec; 24(6):e13988. PubMed ID: 36349869
[TBL] [Abstract][Full Text] [Related]
53. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
[TBL] [Abstract][Full Text] [Related]
54. Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm.
Chan SY; Hughes RM; Woo K; Perales MA; Neofytos D; Papanicolaou G
Med Mycol; 2020 Nov; 58(8):1029-1036. PubMed ID: 32171012
[TBL] [Abstract][Full Text] [Related]
55. Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability.
Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
Ther Drug Monit; 2017 Apr; 39(2):93-101. PubMed ID: 28282366
[TBL] [Abstract][Full Text] [Related]
56. Antifungal Prophylaxis and Treatment Among Lung Transplant Recipients in Early Postoperative Stage: A Single-Center Study.
Pióro A; Latos M; Urlik M; Stącel T; Gawęda M; Pandel A; Przybyłowski P; Knapik P; Ochman M
Transplant Proc; 2022 May; 54(4):1104-1108. PubMed ID: 35437151
[TBL] [Abstract][Full Text] [Related]
57. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
[TBL] [Abstract][Full Text] [Related]
58. Cost-Effectiveness of Posaconazole vs. First-Generation Triazoles for the Prevention of Invasive Fungal Infections Among High-Risk Patients With Hematological Malignancies in China.
Shi C; Ye J; Xie Y; Dong R; Jin W; Wang L; Fang Y; Shan Q; Lin N
Front Public Health; 2022; 10():884846. PubMed ID: 35655452
[TBL] [Abstract][Full Text] [Related]
59. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
Marks DI; Liu Q; Slavin M
Expert Rev Anti Infect Ther; 2017 May; 15(5):493-502. PubMed ID: 28335642
[TBL] [Abstract][Full Text] [Related]
60. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
